Thrombopoietin and the TPO receptor during platelet storage

被引:15
作者
Xia, Y [1 ]
Li, J [1 ]
Bertino, A [1 ]
Kuter, DJ [1 ]
机构
[1] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Hematol Oncol Unit, Boston, MA 02114 USA
关键词
D O I
10.1046/j.1537-2995.2000.40080976.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: For most cells, the addition of a specific growth factor has improved cellular viability by preventing programmed cell death (apoptosis). To determine whether the platelet-specific hematopoietic growth factor thrombopoietin (TPO) might improve platelet viability, endogenous TPO and the platelet TPO receptor were analyzed during storage, and the effect of recombinant TPO on platelet viability was assessed. STUDY DESIGN AND METHODS: During platelet storage, TPO stability was assessed by SDS-PAGE, TPO receptor function was measured, and the platelet TPO receptor was characterized by a I-125-rHuTPO competitive-binding assay. A recombinant TPO, pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF), was added to platelet concentrates during storage, and its effect on pH, LDH, and metabolic activity was determined. RESULTS: During storage, the molecular weight and concentration of endogenous TPO (125 +/- 19 pg/mL) and exogenous TPO (5720 +/- 140 pg/mL) were constant for 12 days; the number (33 +/- 4), binding affinity (149 +/- 33 pM), and function of the platelet TPO receptors were constant for 7 days. Metabolic activity measured with the MTT and MTS assays closely correlated with changes in the pH and LDH. The addition of PEG-rHuMGDF did not alter the pH, LDH, or metabolic activity of platelets during storage, but it did increase by 65 percent the uptake of S-35-methionine into platelets. Finally, platelet concentrates obtained from donors treated with PEG-rHuMGDF retained normal metabolic activity for 12 days, as compared with 5 to 6 days for normal platelet concentrates. CONCLUSIONS: TPO and its platelet receptor are present in normal amounts and have normal function during platelet storage. The addition of recombinant TPO increased platelet methionine transport but did not alter platelet viability during storage. Other means to prevent apoptosis during platelet storage should be considered, and the measurement of platelet metabolic activity by MTT and MTS assays may assist this effort.
引用
收藏
页码:976 / 987
页数:12
相关论文
共 104 条
[81]  
2-Q
[82]   BIOCHEMISTRY, PHYSIOLOGY, AND FUNCTION OF PLATELETS STORED AS CONCENTRATES [J].
RAO, GHR ;
ESCOLAR, G ;
WHITE, JG .
TRANSFUSION, 1993, 33 (09) :766-778
[83]   Recombinant human thrombopoietin (TPO) stimulates erythropoiesis by inhibiting erythroid progenitor cell apoptosis [J].
Ratajczak, MZ ;
Ratajczak, J ;
Marlicz, W ;
Pletcher, CH ;
Machalinski, B ;
Moore, J ;
Hung, HL ;
Gewirtz, AM .
BRITISH JOURNAL OF HAEMATOLOGY, 1997, 98 (01) :8-17
[84]   BCL-2 AND THE REGULATION OF PROGRAMMED CELL-DEATH [J].
REED, JC .
JOURNAL OF CELL BIOLOGY, 1994, 124 (1-2) :1-6
[85]  
RINDER HM, 1992, BLOOD CELLS, V18, P445
[86]   APPLICATION OF THE MTT ASSAY TO HUMAN-PROSTATE CANCER CELL-LINES INVITRO - ESTABLISHMENT OF TEST CONDITIONS AND ASSESSMENT OF HORMONE-STIMULATED GROWTH AND DRUG-INDUCED CYTOSTATIC AND CYTO-TOXIC EFFECTS [J].
ROMIJN, JC ;
VERKOELEN, CF ;
SCHROEDER, FH .
PROSTATE, 1988, 12 (01) :99-110
[87]  
Rudderow D, 1998, P SOC EXP BIOL MED, V217, P219
[88]   The platelet storage lesion [J].
Seghatchian, J ;
Krailadsiri, P .
TRANSFUSION MEDICINE REVIEWS, 1997, 11 (02) :130-144
[89]  
Sheridan W P, 1997, Curr Opin Hematol, V4, P312
[90]  
Sheridan WP, 1997, PLATELETS, V8, P319